CONTINEUM THERAPEUTICS INC-A (CTNM) Stock Price, Quote, News and Overview
NASDAQ:CTNM - Nasdaq - US21217B1008 - Common Stock - Currency: USD
CTNM Quote, Performance and Key Statistics
6.77
+0.33 (+5.12%)
The current stock price of CTNM is 6.77 USD. In the past month the price decreased by -28.51%.
CTNM Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 66.89 | 824.51B | ||
| JNJ | JOHNSON & JOHNSON | 16.69 | 401.33B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 26.18 | 386.95B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 21.41 | 240.28B | ||
| MRK | MERCK & CO. INC. | 12.39 | 239.09B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.56 | 228.26B | ||
| PFE | PFIZER INC | 8.59 | 151.49B | ||
| SNY | SANOFI-ADR | 14.24 | 148.55B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 53.59 | 123.97B | ||
| GSK | GSK PLC-SPON ADR | 8.29 | 81.62B | ||
| ZTS | ZOETIS INC | 28.78 | 76.29B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 33.71 | 47.88B |
Related stock screener links
About CTNM
Company Profile
Contineum Therapeutics Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in San Diego, California and currently employs 31 full-time employees. The company went IPO on 2024-04-05. Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm is focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation, and immunology (NI&I) indications with high unmet need. Its pipeline includes PIPE-791, CTX-343, and PIPE-307. Its lead asset, PIPE-791, is novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) in development for idiopathic pulmonary fibrosis (IPF) and progressive multiple sclerosis (Progressive MS). The firm is developing CTX-343, a peripherally restricted LPA1R antagonist to further expand clinical indications involving LPA1R antagonism. Its second drug candidate, PIPE-307, is a novel, small molecule, selective inhibitor of M1R, which is in clinical development for the potential treatment of depression and relapse remitting MS (RRMS).
Company Info
CONTINEUM THERAPEUTICS INC-A
3565 General Atomics Court, Suite 200
San Diego CALIFORNIA US
Employees: 31
Company Website: https://www.contineum-tx.com/
Phone: 18583335280
CONTINEUM THERAPEUTICS INC-A / CTNM FAQ
What is the stock price of CONTINEUM THERAPEUTICS INC-A today?
The current stock price of CTNM is 6.77 USD. The price increased by 5.12% in the last trading session.
What is the ticker symbol for CONTINEUM THERAPEUTICS INC-A stock?
The exchange symbol of CONTINEUM THERAPEUTICS INC-A is CTNM and it is listed on the Nasdaq exchange.
On which exchange is CTNM stock listed?
CTNM stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CONTINEUM THERAPEUTICS INC-A stock?
10 analysts have analysed CTNM and the average price target is 29.84 USD. This implies a price increase of 340.69% is expected in the next year compared to the current price of 6.77. Check the CONTINEUM THERAPEUTICS INC-A stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CONTINEUM THERAPEUTICS INC-A worth?
CONTINEUM THERAPEUTICS INC-A (CTNM) has a market capitalization of 174.53M USD. This makes CTNM a Micro Cap stock.
How many employees does CONTINEUM THERAPEUTICS INC-A have?
CONTINEUM THERAPEUTICS INC-A (CTNM) currently has 31 employees.
What are the support and resistance levels for CONTINEUM THERAPEUTICS INC-A (CTNM) stock?
CONTINEUM THERAPEUTICS INC-A (CTNM) has a resistance level at 6.78. Check the full technical report for a detailed analysis of CTNM support and resistance levels.
Is CONTINEUM THERAPEUTICS INC-A (CTNM) expected to grow?
The Revenue of CONTINEUM THERAPEUTICS INC-A (CTNM) is expected to decline by -100% in the next year. Check the estimates tab for more information on the CTNM EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CONTINEUM THERAPEUTICS INC-A (CTNM) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CTNM, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CTNM, evaluating the profitability, health, valuation and growth aspects
- CONTINEUM THERAPEUTICS INC-A (CTNM) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CONTINEUM THERAPEUTICS INC-A (CTNM) Sales and EPS estimates to see what analysts future expectations are.
- CONTINEUM THERAPEUTICS INC-A (CTNM) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CONTINEUM THERAPEUTICS INC-A (CTNM) Insider and Institutional Ownership to learn about the owners and their transactions.
- CONTINEUM THERAPEUTICS INC-A (CTNM) Stock Chart to make your own analysis
- CONTINEUM THERAPEUTICS INC-A (CTNM) Latest news and press-releases to stay up to date.
Does CONTINEUM THERAPEUTICS INC-A (CTNM) stock pay dividends?
CTNM does not pay a dividend.
What is the Price/Earnings (PE) ratio of CONTINEUM THERAPEUTICS INC-A (CTNM)?
The PE ratio for CONTINEUM THERAPEUTICS INC-A (CTNM) is 7.52. This is based on the reported non-GAAP earnings per share of 0.9 and the current share price of 6.77 USD. Check the full fundamental report for a full analysis of the valuation metrics for CTNM.
What is the Short Interest ratio of CONTINEUM THERAPEUTICS INC-A (CTNM) stock?
The outstanding short interest for CONTINEUM THERAPEUTICS INC-A (CTNM) is 5.19% of its float. Check the ownership tab for more information on the CTNM short interest.
CTNM Technical Analysis
CTNM Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to CTNM. CTNM has an excellent financial health rating, but there are some minor concerns on its profitability.
CTNM Financial Highlights
Over the last trailing twelve months CTNM reported a non-GAAP Earnings per Share(EPS) of 0.9. The EPS increased by 193.68% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 45.44% | ||
| ROA | 10.52% | ||
| ROE | 10.81% | ||
| Debt/Equity | 0 |
CTNM Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to CTNM. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of -316.16% and a revenue growth -100% for CTNM